Incyte (INCY) risk factors, FY2025 10-K

RISKS RELATING TO COMMERCIALIZATION OF OUR PRODUCTS

1. 01We depend heavily on our lead product, JAKAFI (ruxolitinib), which is marketed as JAKAVI outside the United States. If we are unable to maintain revenues from JAKAFI or those revenues decrease, our business may be materially harmed23% rewritten
2. 02If we are unable to obtain, or maintain at anticipated levels, coverage and reimbursement for our products from government health administration authorities, private health insurers and other organizations, our pricing may be affected and our product sales, results of operations and financial condition could be harmed
3. 03If we are unable to establish and maintain effective sales, marketing and distribution capabilities, or to enter into agreements with third parties to do so, we will not be able to successfully commercialize our products23% rewritten
4. 04If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity
5. 05If the use of our products harms patients, or is perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims35% rewritten
6. 06If our products are used by a wide patient population, new risks and side effects may be discovered, the rate of known risks or side effects may increase, and risks previously viewed as less significant could be determined to be significant27% rewritten
7. 07If we market our products in a manner that violates various laws and regulations, we may be subject to civil or criminal penalties
8. 08Competition for our products could harm our business and result in a decrease in our revenue49% rewritten
9. 09We may be unsuccessful in our efforts to discover and develop drug candidates and commercialize drug products
10. 10If we or our collaborators are unable to obtain regulatory approval for our drug candidates in the United States or foreign jurisdictions, we or our collaborators will not be permitted to commercialize products resulting from our research54% rewritten
11. 11Changes in government pricing policies, including the enactment of “most favored nation” pricing legislation, could adversely affect our businessNew
12. 12We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business
13. 13If we fail to enter into additional licensing agreements or if these arrangements are unsuccessful, our business and operations might be adversely affected
14. 14Public health epidemics and pandemics, such as the COVID-19 pandemic, have adversely affected and could in the future adversely affect our business, results of operations, and financial condition
15. 15Even if a drug candidate that we develop receives regulatory approval, we may decide not to commercialize it if we determine that commercialization of that product would require more money and time than we are willing to invest
16. 16We have limited capacity to conduct preclinical testing and clinical trials, and our resulting dependence on other parties could result in delays in and additional costs for our drug development efforts
17. 17Our reliance on other parties to manufacture our drug products and drug candidates could result in a short supply of the drugs, delays in clinical trials or drug development, increased costs, and withdrawal or denial of a regulatory authority’s approval
18. 18If we fail to comply with the extensive legal and regulatory requirements affecting the healthcare industry, we could face increased costs, penalties and a loss of business24% rewritten
19. 19The illegal distribution and sale by third parties of counterfeit or unfit versions of our or our collaborators’ products or stolen products could harm our business and reputation
20. 20As most of our drug discovery and development operations are conducted at our headquarters in Wilmington, Delaware, the loss of access to this facility would negatively impact our business
21. 21We depend on key employees in a competitive market for skilled personnel, and the loss of the services of any of our key employees or our inability to attract and retain additional personnel would affect our ability to expand our drug discovery and development programs and achieve our objectives
22. 22If we fail to manage our growth effectively, our ability to develop and commercialize products could suffer
23. 23We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management’s attention and harm our operating results and prospects
24. 24Risks associated with our operations outside of the United States could adversely affect our business
25. 25If product liability lawsuits are brought against us, we could face substantial liabilities and may be required to limit commercialization of our products and our results of operations could be harmed
26. 26Because our activities involve the use of hazardous materials, we may be subject to claims relating to improper handling, storage or disposal of these materials that could be time consuming and costly
27. 27Business disruptions and uncertainties could seriously harm our operations, future revenues and financial condition and increase our costs and expenses36% rewritten

RISKS RELATING TO OUR FINANCIAL RESULTS

1. 28We may incur losses in the future, and we expect to continue to incur significant expenses to discover and develop drugs, which may make it difficult for us to achieve sustained profitability on a quarterly or annual basis in the future70% rewritten
2. 29The development of drug products will require us to spend significant funds on research, development, testing, obtaining regulatory approvals, manufacturing and marketing. We cannot be sure that we will generate substantial revenues from any drug candidates that we license or develop for several years, if everNew
3. 30Our future funding requirements will depend on many factors and we anticipate that we may need to raise additional capital to fund our business plan and research and development efforts going-forward
4. 31We invest our cash in accordance with an established internal policy and customarily in money market funds, U.S. government backed-funds and Treasury securities, which are investment grade and historically have been highly liquid and carried relatively low risk
5. 32Changes in tax laws or regulations could adversely affect our results of operations, business and financial condition44% rewritten

RISKS RELATING TO INTELLECTUAL PROPERTY AND LEGAL MATTERS

1. 33If we are subject to arbitration, litigation and infringement claims, they could be costly and disrupt our drug discovery and development efforts
2. 34We may be unable to adequately protect or enforce our proprietary information, which may result in its unauthorized use, a loss of revenue under a collaboration agreement or loss of sales to generic versions of our products or otherwise reduce our ability to compete in developing and commercializing products
3. 35If the effective term of our patents is decreased due to changes in U.S. patent laws or if we need to refile some of our patent applications, the value of our patent portfolio and the revenues we derive from it may be decreased
4. 36International patent protection is particularly uncertain and costly, and our involvement in opposition proceedings in foreign countries may result in the expenditure of substantial sums and management resources

RISKS RELATING TO INFORMATION TECHNOLOGY AND DATA PRIVACY

1. 37Significant disruptions of information technology systems, breaches of data security, or unauthorized disclosures of personal information (including sensitive personal information) could adversely affect our business, and could subject us to liability or reputational damage
2. 38Increasing use of social media and new technology, including artificial intelligence, could give rise to liability, breaches of data security, or reputational damage